Karyopharm Therapeutics's market cap is currently $77.01M. The company's EPS TTM is $-1.142; its P/E ratio is ―; Karyopharm Therapeutics is scheduled to report earnings on February 27, 2025, and the estimated EPS forecast is $-0.27. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 146.03M	$ 157.07M	$ 209.82M	$ 108.08M	$ 40.89M
Gross Profit	$ 141.09M	$ 151.86M	$ 206.42M	$ 105.38M	$ 38.49M
Operating Income	$ -129.54M	$ -142.20M	$ -98.27M	$ -171.85M	$ -189.28M
EBITDA	$ -118.42M	$ -139.31M	$ -96.98M	$ -167.85M	$ -182.93M
Net Income	$ -143.10M	$ -165.29M	$ -124.09M	$ -196.27M	$ -199.59M
Balance Sheet
Cash & Short-Term Investments	$ 191.44M	$ 277.97M	$ 228.62M	$ 273.45M	$ 263.97M
Total Assets	$ 240.44M	$ 358.17M	$ 305.31M	$ 313.05M	$ 294.96M
Total Debt	$ 177.02M	$ 172.98M	$ 169.29M	$ 117.93M	$ 109.86M
Net Debt	$ 124.78M	$ 37.79M	$ -21.17M	$ 32.01M	$ -19.00M
Total Liabilities	$ 376.64M	$ 374.83M	$ 384.98M	$ 262.50M	$ 245.19M
Stockholders' Equity	$ -136.21M	$ -16.66M	$ -79.67M	$ 50.55M	$ 49.77M
Cash Flow
Free Cash Flow	$ -92.72M	$ -149.67M	$ -112.83M	$ -160.38M	$ -191.03M
Operating Cash Flow	$ -92.72M	$ -149.55M	$ -107.12M	$ -160.23M	$ -190.82M
Investing Cash Flow	$ 7.94M	$ -104.26M	$ 141.84M	$ -53.69M	$ 78.45M
Financing Cash Flow	$ 1.12M	$ 193.74M	$ 73.65M	$ 172.08M	$ 124.31M

Currency in USD

Karyopharm Therapeutics Earnings and Revenue History

Income Statement >

Karyopharm Therapeutics Debt to Assets

Balance Sheet >

Karyopharm Therapeutics Cash Flow

Cash Flow >

Karyopharm Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing